Tremfya 100 mg/1 ml pref. syringe for s.c

Tremfya 100 mg/1 ml pref. syringe for s.c

34757.00 جنيها

معلومات الدواء

الإسم التجاري

Tremfya 100 mg/1 ml pref. syringe for s.c -

الإسم العلمي 

Guselkumab

الشركات المنتجة

Janssen cilag, Soficopharm,
Pharmacology
guselkumab is a human igg1-gamma monoclonal antibody (mab) that binds selectively to interleukin 23 (il-23) protein with high specificity and affinity. il-23 a regulatory cytokine affects the differentiation expansion and survival of t cell subsets (e.g. th17 cells and tc17 cells) and innate immune cell subsets which represent sources of effector cytokines including il-17a il-17f and il-22 that drive inflammatory disease. in humans selective blockade of il-23 was shown to normalize production of these cytokines.
il-23 levels are elevated in the skin of patients with plaque psoriasis. in in vitro guselkumab was shown to inhibit bioactivity of il-23 by blocking its interaction with cell surface il-23 receptor disrupting il-23-mediated signaling activation and cytokine cascades. guselkumab exerts clinical effects in plaque psoriasis through blockade of the il-23 cytokine pathway.

indications
treatment of moderate to severe plaque psoriasis
Pharmacology
guselkumab is a human igg1-gamma monoclonal antibody (mab) that binds selectively to interleukin 23 (il-23) protein with high specificity and affinity. il-23 a regulatory cytokine affects the differentiation expansion and survival of t cell subsets (e.g. th17 cells and tc17 cells) and innate immune cell subsets which represent sources of effector cytokines including il-17a il-17f and il-22 that drive inflammatory disease. in humans selective blockade of il-23 was shown to normalize production of these cytokines.
il-23 levels are elevated in the skin of patients with plaque psoriasis. in in vitro guselkumab was shown to inhibit bioactivity of il-23 by blocking its interaction with cell surface il-23 receptor disrupting il-23-mediated signaling activation and cytokine cascades. guselkumab exerts clinical effects in plaque psoriasis through blockade of the il-23 cytokine pathway.

indications
treatment of moderate to severe plaque psoriasis

تنبيه بخصوص المعلومات المتوفرة علي موقع دليل الدواء

بينما نعمل دائما علي تنقيح وتحسين البيانات المعروضة علي موقعنا إلا أننا ننصح دائما بعدم تعاطي أي دواء بدون إستشارة الطبيب المختص، ولا يتحمل الموقع أي مسئولية ناتجة عن سوء استخدام الأدوية بدون استشارة المختص، في حال وجدت أي بيانات خاطئة أو سعر دواء غير صحيح برجاء الإتصال بنا لتصحيحه.
الإبلاغ عن مشكلة

البدائل

4 دواء
اسم الدواء
السعر